EUVIMEDEUVIMED entdecken
Crossref

Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors

Jeesoo Choi, Ju-Young Shin, Taeyul K Kim, Kiwook Kim, Jiyun Kim, Eunhye Jeon, Juyeong Park, Yoon Dae Han, Kyung-A Kim, Taebo Sim, Hui Kwon Kim, Han Sang Kim

Cancer Letters · 2024-06 · 591 · 216904

DOI: 10.1016/j.canlet.2024.216904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-06. Verfasst von Jeesoo Choi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Rep…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Drug Resistance, Neoplasm, Mutation, Mutagenesis, Site-Directed. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Ministry of Health and Welfare, Yonsei University College of Medicine, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS plays a crucial role in regulating cell survival and proliferation and is one of the most commonly mutated oncogenes in human cancers. The novel KRASG12D inhibitor, MRTX1133, demonstrates promising antitumor efficacy in vitro and in vivo. However, the development of acquired resistance in treated patients presents a considerable challenge to sustained therapeutic effectiveness. In response to this challenge, we conducted site-specific mutagenesis screening to identify potential secondary mutations that could induce resistance to MRTX1133. We screened a range of KRASG12D variants harboring potential secondary mutations, and 44 representative variants were selected for in-depth validation of the pooled screening outcomes. We identified eight variants (G12D with V9E, V9W, V9Q, G13P, T58Y, R68G, Y96W, and Q99L) that exhibited substantial resistance, with V9W showing notable resistance, and downstream signaling analyses and structural modeling were conducted. We observed that secondary mutations in KRASG12D can lead to acquired resistance to MRTX1133 and BI-2865, a novel pan-KRAS inhibitor, in human cancer cell lines. This evidence is critical for devising new strategies to counteract resistance mechanisms and, ultimately, enhance treatment outcomes in patients with KRASG12D-mutant cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Drug Resistance, NeoplasmMutationMutagenesis, Site-DirectedHumansCell Line, TumorAntineoplastic AgentsCell Proliferation

Stichwörter der Autor:innen

Drug resistanceKRAS inhibitorSite-specific mutagenesis screening

Substanzen

Proto-Oncogene Proteins p21(ras)Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
  • Department of Integrative Biotechnology, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
  • Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
  • Department of Medicine, Graduate School, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea; Theragen Bio Co., Ltd, Seongnam-si, 13488, Republic of Korea.
  • Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
  • Severance Biomedical Science Institute, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea; KU-KIST Graduate School of Converging Science a…

Förderung

  • Ministry of Health and Welfare
  • Yonsei University College of Medicine
  • Korea Health Industry Development Institute
  • Ministry of Science, ICT and Future Planning
  • Ministry of Trade, Industry and Energy
  • National Research Foundation of Korea
  • Yonsei University

Zitieren

APA

Choi, J., Shin, J. Y., Kim, T. K., Kim, K., Kim, J., Jeon, E., Park, J., Han, Y. D., Kim, K. A., Sim, T., Kim, H. K., & Kim, H. S. (2024). Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors. Cancer Letters, 591, 216904. https://doi.org/10.1016/j.canlet.2024.216904

Vancouver

Choi J, Shin JY, Kim TK, Kim K, Kim J, Jeon E, et al. Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors. Cancer Letters. 2024;591:216904. doi:10.1016/j.canlet.2024.216904

BibTeX
@article{Choi2024,
  author = {Choi, Jeesoo and Shin, Ju-Young and Kim, Taeyul K and Kim, Kiwook and Kim, Jiyun and Jeon, Eunhye and Park, Juyeong and Han, Yoon Dae and Kim, Kyung-A and Sim, Taebo and Kim, Hui Kwon and Kim, Han Sang},
  title = {Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors},
  journal = {Cancer Letters},
  year = {2024},
  volume = {591},
  pages = {216904},
  doi = {10.1016/j.canlet.2024.216904}
}
Kostenlos starten →